Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2021 | COLOR: Complex PCI via Transradial vs Transfemoral Approach

Treating total occlusions, complex bifurcations, grossly calcified lesions or left main lesions via transradial approach is associated with significant reduction in access-site bleeding or vascular complications vs transfemoral approach. This kind of procedures have been typically excluded from studies randomizing patients to transradial vs transfemoral approach. 

EuroPCR 2021 | COLOR: Angioplastias complejas por acceso radial vs femoral

The COLOR study used the transradial bore-guiding catheter Glidesheath (produced by Terumo) with a much thinner wall that enables the use of 7 French devices in 6 French access sites. 

Guidelines on both sides of the Atlantic recommend the transradial approach over the transfemoral because of its capacity to reduce bleeding, vascular complications and even mortality (RIFLE-STEACS y MATRIX). 

Despite the latter, there are many operators that given the need for a larger bore-guiding catheter, opt for the transfemoral approach. Curiously, choosing one over the other varies according to center, country, and ever operator age. 

The COLOR study was presented at EuroPCR 2021 scientific sessions and was simultaneously published in JACC: Cardiovascular Interventions. It included 388 patients with planned complex PCI requiring 7 French catheters. 

Over half of these procedures were total occlusions (58%), followed by calcified lesions (19%), left main lesions (14%) and 2 stent bifurcations (9%).


Read also: EuroPCR 2021 | TVT Registry: Outcomes of TAVR in Low Surgical Risk Bicuspids.


Procedural success was around 90% in both arms and the use of a different approach to the one indicated by randomization (crossover rate) was low, and similar between arms. 

The combined primary end point of BARC bleeding 2/3/5 or vascular complication requiring intervention, occurred in 19.1% of patients in the transfemoral group vs. 3.6% in the transradial group. The difference in bleeding was basically driven by BARC 2 bleeding (apparent bleeding, but with no clinical compromise). Vascular complications were 4.1% vs 0.5% respectively (p=0.04).

Major cardiovascular events at 30 days showed a tendency in favor of the femoral access (2.6% vs 6.7%; p=0.06). This should be interpreted with caution seeing as the COLOR did not reach the statistical power to show differences in clinical events.  

Original Title: Randomized Comparison Between Radial and Femoral Large-Bore Access for Complex Percutaneous Coronary Intervention.

Reference: Thomas A Meijers et al. JACC Cardiovasc Interv. 2021 May 7;S1936-8798(21)00513-6. Online ahead of print. doi: 10.1016/j.jcin.2021.03.041.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...